Haemostatic Disorders
Hemab ApS focuses on Glanzmann thrombasthenia, a rare platelet function disorder associated with impaired clot formation and recurrent bleeding.
- Bleeding frequency
- Bleeding severity
- Platelet-mediated haemostasis
The sponsor’s research interest centres on clinical outcomes linked to bleeding control and the management of inherited disorders of haemostasis.
Rare Blood Disease Therapeutics
The company is active in therapeutic development for rare haematologic diseases, with an emphasis on conditions where conventional treatment options remain limited.
- Inherited bleeding disorders
- Prophylactic treatment
- Long-term bleeding prevention
Its clinical work reflects a focus on therapies intended to reduce bleeding burden in patients with persistent coagulation-related vulnerability.
Protein Therapeutics
Hemab ApS’s research landscape includes biologic therapy development aimed at restoring or supporting normal clotting function in platelet disorders.
- Safety and tolerability
- Pharmacokinetics
- Pharmacodynamics
Clinical interest extends to repeated administration and the assessment of treatment effects on bleeding protection.
Translational Clinical Development
The sponsor is engaged in early clinical research across multiple countries, with activity distributed among collaborating sites in Europe and other regions.
- Multinational clinical research
- Recruiting studies
- Specialist trial sites
This research setting supports evaluation of novel treatments for inherited bleeding conditions within a focused clinical network.
